Effects of Flaxseed Supplementation in Metabolic Syndrome
Primary Purpose
Metabolic Syndrome
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
flaxseed
lifestyle modification
Sponsored by
About this trial
This is an interventional treatment trial for Metabolic Syndrome
Eligibility Criteria
Inclusion Criteria:
- 18 years of age and older
- having three of the following five features: Increased waist circumference (≥102 cm in men and ≥88 cm in women), elevated TG (≥150 mg/dl), reduced HDL-C (≤40 mg/dl in men and ≤50 mg/dl in women), elevated blood pressure (≥130/85 mm Hg or on treatment for hypertension) and elevated glucose (≥100 mg/dl), according to the National Cholesterol Education Program Adult Treatment Panel III report
Exclusion Criteria:
- history of allergy or high consumption of nuts, flaxseed, or sesame seeds
- clinically diagnosed renal, liver, heart, pituitary, thyroid, or psychiatric disorders impairing the patient's ability to provide written informed consent
- history of cardiovascular diseases, cancers, alimentary tract disorders affecting absorption
- pregnancy, lactation, and lack of effective birth control in women of child-bearing potential
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Flaxseed
control
Arm Description
30 g milled brown flaxseed + lifestyle modification
lifestyle modification including dietary and physical activity recommendation
Outcomes
Primary Outcome Measures
Insulin resistance index (HOMA-IR)
The homeostatic model assessment (HOMA)
Secondary Outcome Measures
Full Information
NCT ID
NCT02497352
First Posted
July 10, 2015
Last Updated
July 13, 2015
Sponsor
National Nutrition and Food Technology Institute
1. Study Identification
Unique Protocol Identification Number
NCT02497352
Brief Title
Effects of Flaxseed Supplementation in Metabolic Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
February 2014 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Nutrition and Food Technology Institute
4. Oversight
5. Study Description
Brief Summary
To evaluate the effects of flaxseed supplementation on fasting blood sugar, lipid profile and anthropocentric measurements in subjects with metabolic syndrome, in a randomized, open-labeled, controlled pilot study, 44 subjects with metabolic syndrome will be received 30g/d flaxseed with lifestyle modification or lifestyle modification alone for 12 weeks. Both groups will be advised to follow an energy balanced diet and physical activity recommendations. Parameters related to metabolic syndrome will be measured at the baseline and at the end of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Flaxseed
Arm Type
Experimental
Arm Description
30 g milled brown flaxseed + lifestyle modification
Arm Title
control
Arm Type
Active Comparator
Arm Description
lifestyle modification including dietary and physical activity recommendation
Intervention Type
Dietary Supplement
Intervention Name(s)
flaxseed
Intervention Type
Behavioral
Intervention Name(s)
lifestyle modification
Primary Outcome Measure Information:
Title
Insulin resistance index (HOMA-IR)
Description
The homeostatic model assessment (HOMA)
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age and older
having three of the following five features: Increased waist circumference (≥102 cm in men and ≥88 cm in women), elevated TG (≥150 mg/dl), reduced HDL-C (≤40 mg/dl in men and ≤50 mg/dl in women), elevated blood pressure (≥130/85 mm Hg or on treatment for hypertension) and elevated glucose (≥100 mg/dl), according to the National Cholesterol Education Program Adult Treatment Panel III report
Exclusion Criteria:
history of allergy or high consumption of nuts, flaxseed, or sesame seeds
clinically diagnosed renal, liver, heart, pituitary, thyroid, or psychiatric disorders impairing the patient's ability to provide written informed consent
history of cardiovascular diseases, cancers, alimentary tract disorders affecting absorption
pregnancy, lactation, and lack of effective birth control in women of child-bearing potential
12. IPD Sharing Statement
Learn more about this trial
Effects of Flaxseed Supplementation in Metabolic Syndrome
We'll reach out to this number within 24 hrs